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Systematic reviews and meta-analyses of randomized trials that include patient-reported outcomes (PROs) often
provide crucial information for patients, clinicians and policy-makers facing challenging health care decisions. Based
on emerging methods, guidance on improving the interpretability of meta-analysis of patient-reported outcomes,
typically continuous in nature, is likely to enhance decision-making. The objective of this paper is to summarize
approaches to enhancing the interpretability of pooled estimates of PROs in meta-analyses. When differences in
PROs between groups are statistically significant, decision-makers must be able to interpret the magnitude of effect.
This is challenging when, as is often the case, clinical trial investigators use different measurement instruments for
the same construct within and between individual randomized trials. For such cases, in addition to pooling results
as a standardized mean difference, we recommend that systematic review authors use other methods to present
results such as relative (relative risk, odds ratio) or absolute (risk difference) dichotomized treatment effects, complimented
by presentation in either: natural units (e.g. overall depression reduced by 2.4 points when measured on a 50-point
Hamilton Rating Scale for Depression); minimal important difference units (e.g. where 1.0 unit represents the smallest
difference in depression that patients, on average, perceive as important the depression score was 0.38 (95% CI
0.30 to 0.47) units less than the control group); or a ratio of means (e.g. where the mean in the treatment group
is divided by the mean in the control group, the ratio of means is 1.27, representing a 27% relative reduction in
the mean depression score).Introduction
Clinical trials evaluating medical treatments and health
interventions increasingly incorporate self-reported mea-
sures from patients, often referred to as patient-reported
outcomes (PROs). A PRO is defined as “any report of the
status of a patient’s health condition that comes directly
from the patient without interpretation of the patient’s
response by a clinician or anyone else” [1]. Systematic
reviews and meta-analyses of clinical trials often include
PROs. In Part 1 of this series, we addressed the import-
ance of PROs for health care decision-making, illustrated
the key risk of bias issues that systematic reviews of PROs* Correspondence: bradley.johnston@sickkids.ca
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reproduction in any medium, provided the orshould consider and provided guidance on combining
PROs in meta-analyses [2]. Part 1 used examples of PROs
employed in assessing and summarizing post-operative
pain and chronic obstructive pulmonary disease outcomes,
while in this article, in addition to using examples of
chronic obstructive pulmonary disease–we primarily use
an example of summarizing PROs from clinical trials in
depression. The structure of this article borrows from a
recent article we published on preparing Summary of
Findings tables for systematic reviews of continuous
outcomes prepared by the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) work-
ing group [3]. Summary of Findings tables are an approach
the GRADE working group developed for the presentation
of findings particular to each outcome of interest in system-
atic reviews and meta-analysis. The tables have been devel-
oped for the presentation of continuous and dichotomousal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Johnston et al. Health and Quality of Life Outcomes 2013, 11:211 Page 2 of 9
http://www.hqlo.com/content/11/1/211outcomes [3,4]. The purpose of this article is to summarize
five presentation approaches to enhancing the interpretabil-
ity of pooled estimates of PROs.
Methods for improving the interpretability of
pooled data
Meta-analyses of clinical trials routinely provide enough
information for decision-makers to evaluate the extent to
which chance can explain apparent differences between
interventions. The interpretation of the magnitude of
treatment effects is typically more challenging. First, if
trials have used the same instrument, decision-makers
may have difficulty interpreting the size of the effect.
For instance, if told that the weighted mean difference
between rehabilitation and standard care in a series of
randomized trials using the Chronic Respiratory Ques-
tionnaire (CRQ) was 1.0 (95% CI 0.6-1.5), many readers
would have no idea if this represents a trivial, small but
important, moderate, or large effect [5-7].
The situation becomes even more challenging when
trials use different instruments to measure the same or
similar constructs. For instance, there are at least five
instruments available to measure health-related quality of
life (HRQoL) in patients with chronic obstructive respira-
tory disease (Chronic Respiratory Questionnaire, Clinical
COPD Questionnaire, Pulmonary Functional Status and
Dyspnea Questionnaire, Seattle Obstructive Lung Disease
Questionnaire, St George’s Respiratory Questionnaire) [8].
We will deal with these two situations–all trials having
used the same instrument, and trials having used different
instruments–in turn.
Summarizing a single PRO: beyond a mean difference
and statistical significance
On occasion, individual studies using continuous vari-
ables will provide data that facilitate creating meaningful
dichotomies. For example, studies of the impact of throm-
bolytic therapy after stroke typically use the Rankin instru-
ment that classifies patients into one of six categories of
disability from no symptoms to severe handicap requiring
constant attention. Authors of a systematic review evaluat-
ing the impact of thrombolytic therapy in patients with
stroke dichotomized the Rankin instrument, creating a
“bad outcome” category of those dead, or moderately or
severely disabled (which they labelled as “dependent”) and
a “good outcome” category of those with no symptoms, no
significant disability, slight disability or moderate disability
[9]. The reviewers were therefore able to present results
showing that thrombolytic therapy significantly reduced
the proportion of patients who were dead or dependent at
the end of 3 to 6 months of follow-up (OR 0.81, 95% CI
0.73 to 0.90). This presentation facilitates interpretation by
the review’s readers. A priori, reviewers should choose and
justify their threshold when dichotomizing PROs, andconsider conducting sensitivity analyses providing results
for reasonable and extreme thresholds to support a better
understanding of the generalizability of the results.
When authors do not provide information that would
facilitate meaningful dichotomies, the systematic reviewer
can aid interpretation by reporting the range of possible
results, and the range of means in treatment and control
groups in the studies. Particularly useful–if it is available–
is an estimate of the smallest difference that patients
are likely to consider important (the minimally important
difference or MID). There are a variety of methods for
generating estimates of the MID [10,11], the application of
which can lead to statements such as the following in a
systematic review of the impact of respiratory rehabilita-
tion in patients with chronic lung disease on HRQoL: “for
each of the Chronic Respiratory Questionnaire domains
(dyspnea, fatigue, emotional function and mastery), the
common effect size exceeded the MID (0.5 point on
the 7-point scale).” Authors also reported that for each
of the Chronic Respiratory Questionnaire domains, the
lower limit of the confidence interval around the com-
mon treatment effect exceeded the MID (e.g. dyspnea
domain: 1.0; 95% CI 0.8-1.2) [12].
Although this is very helpful, it potentially tempts cli-
nicians to make inappropriate inferences. If the MID is
0.5 and the mean difference between treatments is 0.4,
clinicians may infer that nobody benefits from the inter-
vention; if the mean difference is 0.6, they may conclude
that everyone benefits. Both inferences are a misin-
terpretation as they ignore the distribution of benefit
between individuals. We suggest the following guide for
interpretation given a 0.5 MID: if the pooled estimate is
greater than 0.5, and one accepts that the estimate of
effect is accurate, many patients may gain important
benefits from treatment. If the estimate of effect lies
between 0.25 and 0.5, the treatment may benefit an
appreciable number of patients. As the pooled estimate
falls below 0.25 (i.e. 50% of the MID), it becomes progres-
sively less likely that an appreciable numbers of patients
will achieve important benefits from treatment.
More than one PRO: beyond a standardized mean
difference & statistical significance
As the prior discussion pointed out, when pooling across
different PROs that measure a common construct the
weighted mean difference is much more challenging to
generate and we therefore replace it with a unitless
measure of effect called the standardized mean differ-
ence (SMD) or “effect size”. This involves dividing the
difference between the intervention and control means
in each trial (i.e., the mean difference) by the estimated
between-person standard deviation (SD) for that trial
[13]. The SMD expresses the intervention effect in SD
units rather than the original units of measurement, with
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effect (the difference between means) and the SD of the
outcomes (the inherent variability among participants).
This approach has a number of limitations. First, decision-
makers will not have an intuitive sense of the importance
of the effect on the basis of the SD unit report. Second,
it has statistical limitations (the same effect will appear
different if population heterogeneity across eligible trials
differs) [14].
Unfortunately, there is no fully satisfactory way of pro-
viding a sense of the magnitude of effect for a PRO when
one has had to resort to effect sizes to generate a summary
estimate. One can offer readers standard rules of thumb in
interpretation of effect sizes (for instance 0.2 represents a
small effect, 0.5 a moderate effect, and 0.8 a large effect
[15] or some variation (for instance, <0.40 = small, 0.40 to
0.70 =moderate, >0.70 = large). However, effect size inter-
pretations are often disease-specific and context-specific,
further warranting an explanation for the reader. Another,
perhaps even less satisfactory approach suggests that a
standardized mean difference of 0.5 approximates, in
many cases, the MID [16,17]. It is, however, very unlikely
that a single SD ratio (explained below) will apply to all
instruments.
When at least one instrument has an established anchor-
based MID, the MID to SD ratio (SD ratio) may provide
an estimate of MID values for instruments without an
established MID. For a given PRO instrument, the SD
ratio is the anchor-based MID divided by the baseline
SD (or, if not reported, the end-of-treatment SD for the
control group). When several SDs are available from a
number of trials, a median SD ratio can be computed, and
can be used to estimate the MID for a PRO instrument
for which an anchor-based MID is not established. This
is done by multiplying the SD by the median SD ratio
[18]. This method assumes that the SD ratio is relatively
constant across a range of PRO instruments measuring
the same or similar constructs (e.g. disease-specific quality
of life) in similar populations. For instance, the SD ratios
based on the four instruments with known anchor-based
MIDs were 0.26 (St George’s Respiratory Question-
naire), 0.51 (Chronic Respiratory Questionnaire), 0.34
(Montgomery Asberg Depression Rating Scale (MADRS))
and 0.86 (17-item Hamilton Rating Scale for Depression
(HRSD)). These findings suggest that a single SD ratio
based on average ratios between MIDs and baseline
SDs is very unlikely to apply to all instruments and
advocate the need for sensitivity analyses to explore
the extent to which pooled estimates are robust to a
variety of MID estimates [18].
Many authors have proposed alternatives to the SMD
that produce summary estimates that clinicians can
interpret more easily, some of which rely on standard
deviations being similar across trials, and some of whichdo not [14,18-22]. Thus far, alternatives to the SMD have
seen limited use and few studies have compared the SMD
approach to the available alternatives [14,19,23-26].
Despite their limited use, the alternative approaches to
summarizing results to enhance interpretability can be
very useful. Consider, for instance, a systematic review
assessing paroxetine vs placebo for the treatment of major
depression in adults, which included 34 randomized trials
employing the HRSD (n = 30) and the MADRS (n = 4)
[27]. The MADRS ratings can be added to form an overall
score ranging from 0 to 60; whereas for the HRSD, a num-
ber of versions exist, the most common being the 17-item
HRSD, with overall scores ranging from 0 to 50 [28]. The
majority of the included trials employing the HRSD
used the 17-item version. Investigators have established
3 as the anchor-based MID for the 60-point Montgomery
Asberg Depression Rating Scale [29] and 7 as the anchor-
based MID for the 50-point Hamilton Rating Scale for
Depression [30]. Providing pooled estimates of effect and
making results interpretable for decision-makers mandates
use of one of five available presentation approaches that
we will summarize here, the merits of which–and our
associated recommendations–are presented in Table 1.
The five presentation approaches discussed are: standard
deviation units (i.e. the standardized mean difference);
conversion to the natural units of the most common
instrument; conversion to dichotomized relative and
absolute effects; ratio of means; and minimally import-
ant difference units.
Presentation approaches
Standard deviation units - standardized mean difference
One way of generating a pooled estimate when trials have
measured the same construct with different instruments
is to divide the difference between the intervention and
control means (i.e., the difference in means) in each trial
by the estimated between-person standard deviation (SD)
(see row A in Table 2 [13]. This measure is often referred
to as the standardized mean difference (SMD) or Cohen’s
effect size.
Presenting results in SD units (as an SMD) is by far the
longest standing and most widely used approach and is
recommended in the Cochrane Handbook [13]. Calculat-
ing and presenting results in SD units has, however, major
limitations. First, clinicians and their patients are unlikely
to be able to relate to this way of presenting results [26].
Second, if the variability or heterogeneity in the severity of
patients’ condition (and thus the variability in scores on
the chosen outcome) varies between trials, the SDs will
also vary. As a result, trials that enrol heterogeneous
groups of patients will yield smaller SMDs than trials
enrolling less heterogeneous patients, even if the actual
(not standardized) mean difference estimates–and thus
the absolute estimate of the magnitude of treatment
Table 1 Five approaches to presenting pooled PRO variables when primary studies have used different instruments to measure the same construct
Approach Description Advantages Disadvantages Recommendation
(A) Standard deviation (SD) units
(standardized mean difference;
effect size)
The pooled mean difference is presented
in standard deviation units
(+) Widely used (−) Interpretation challenging Consider complimenting other approaches
with this; it is not recommended to use
this approach independently.(−) Misleading when trial SDs
are heterogeneous
(B) Natural units Linear transformation of trial data to most
familiar scale
(+) Easier to interpret if scale
well-known
(−) Few instruments in clinical
practice are easy to interpret
Approaches to conversion to natural units
include those based on SD units and re-scaling
approaches. We suggest the latter. In rare situations
when instrument very familiar to front line clinicians
seriously consider this presentation
(C) Relative and absolute
dichotomized effects
Obtain proportion above threshold in both
groups and calculate relative or absolute
binary effect measure
(+) Very familiar to clinical
audiences
(−) Involve statistical
assumptions that may be
questionable
If the minimal important difference is known use this
strategy in preference to relying on SD units
Always seriously consider this option
(D) Ratio of means The ratio between the mean responses in
the intervention and control group
(+) May be easily
interpretable to clinical
audience
(−) Not applicable for change
scores
Consider as complementing other approaches,









The pooled mean differences is presented
in MID units
(+) May be easily
interpretable to clinical
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(−) Only applicable when
minimally important difference
is known
Consider as complementing other approaches,
























Table 2 Application of summary approaches to paroxetine vs placebo for major depression in adults









(A) Standard deviation units The depression score in the paroxetine groups
was on average 0.31 SDs (0.24 to 0.38 lower




As a rule of thumb, 0.2 SD represents
a small difference, 0.5 moderate, and
0.8 large (Cohen, 1988)
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Hamilton Rating Scale for
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average only 2.47 lower, the
corresponding NNT is 11







This approach uses binomial and equal
variance assumptions and baseline risks,
and demonstrates that for every 100




0.11 (95% CI 0.07 to 0.16) in
favor
of paroxetine







Weighted average of the mean depression
score in paroxetine group divided by mean
depression score in placebo. RoM method
provides similar effect estimates compared
with the traditionally used standard
deviation unit, with SMDs of 0.2, 0.5, and
0.8, corresponding to increases in RoM of






The depression score in the paroxetine groups was on
average 0.38 (95% CI 0.30 to 0.47) minimal important




An effect less than half the minimal
important difference suggests a
small effect
Note: Investigators measured depression using different instruments, higher scores indicate more severe depression. 1Quality rating from 1 (very low quality) to 4 (high quality); 2Evidence limited by heterogeneity























Johnston et al. Health and Quality of Life Outcomes 2013, 11:211 Page 6 of 9
http://www.hqlo.com/content/11/1/211effect–is similar across all trials. Finally, if very homo-
genous populations are enrolled, SD units can give a
misleading, inflated impression of the magnitude of treat-
ment effect.
In Table 2, the presentation in SD units suggest a
small treatment effect. The structure of the Summary
of Findings table, however, is not well suited to this
presentation. If authors use the SMD, it is not sensible
to present absolute values in the intervention and com-
parison groups because studies have used different
measurement instruments with different units. One
approach to this dilemma, presented in Table 2, is to
present the SMD in place of the two columns usually
devoted to absolute rates. An alternative is to present
the median value from the studies that used the most
familiar measure of the concept in the control group
column, and the SMD in the intervention group column.
To aid interpretability of a metric unfamiliar to clinicians
or patients, a comment provides a rule-of-thumb guide
to the significance of various effect sizes [15] (see row
A, Table 2).
Conversion into units of the most commonly used
instrument
A second approach (see row B in Table 2) converts the
effect size back into the natural units of the outcome
measure most familiar to the target audience(s). There
are two statistical approaches to making the conversion.
One calculates the absolute difference in means by multi-
plying the SMD by an estimate of the SD associated with
the most familiar instrument. For example, one might
assume that the HRSD, a 0 to 50 point measure with
evidence of reliability and validity, is the most familiar
depression instrument among decision-makers [31]. In
this case the magnitude of effect for the chosen instru-
ment is 2.47. This result would be of limited use without
knowledge of the MID, and thus the comment includes
the estimated MID (7 points) [30], suggesting a small, and
perhaps very small, effect (row B, Table 2).
The other statistical approach makes a simple conver-
sion–before pooling and without calculating the SMD–
of other instruments to the units of the most familiar
instrument [25]. In this case, we chose the Hamilton
Rating Scale for Depression, and re-scaled the mean
and SD of the other instruments to HRSD units. Given
the MID of the HRSD (7 units), the mean difference in
change of 2.50 suggests a small treatment effect of
paroxetine [30].
This second approach, presenting in units of the most
familiar instrument, may be the most desirable when the
target audience(s) have extensive experience with that
instrument, particularly if the MID is well established
[10]. Nevertheless, the natural unit presentation may, in
relation to the MID, still be misleading. In this case, theabsolute difference is less than half the MID. This may
lead clinicians to conclude the effect of treatment is trivial.
While it is correct that the effect is small, as indicated
above, it may still be important. For instance, a mean dif-
ference of 2.50 units in the HRSD (in which the MID is
7.0) is translated into a difference of the proportion of
patients benefiting in experimental and control groups
of 9.2%, and thus a number needed to treat (NNT) of
approximately 11.
Conversion to dichotomized relative and absolute effects
A third approach (see row C in Table 2) converts the
continuous measure into a dichotomy and thus allows
calculation of relative and absolute effects on a binary scale.
One method to generate a dichotomy from continuous
data relies on the SMD and assumes that results of both
treatment and control group are normally distributed and
have equal variances [21,32]. Meta-analysts usually make
these assumptions when they calculate SMDs [21]. We
have used this approach in Table 2, row C, and it suggests
a small relative effect and a small but still potentially
important absolute effect. This approach has the advan-
tage that you can apply it easily by consulting Tables 3 and
4, which provides the relation between the SMD, control
group response rate, and the resulting risk difference.
Table 3 presents the conversion when the outcome is un-
desirable (e.g. depression) and Table 4 when the outcome
is desirable (e.g. response to treatment).
This approach suffers from three important limitations.
First, the dichotomous outcome that the intervention is
decreasing is often not self-evident from the continuous
outcome from which it is derived. We obtain a difference
in the proportion of patients in intervention and control
groups above some threshold, but the choice of that
threshold is often arbitrary. In this example (Table 2,
row C), fortunately, we can specify the threshold as an
important improvement in depression (i.e. a change of 1
MID or more is representative of a 7 point difference on
the HRSD). Second, the method requires investigators
to specify the proportion of control patients with an
improvement of at least one MID. Choosing this propor-
tion may also be difficult. For instance, if one knows that
control group depression scores varied from 23 to 44,
with standard deviations around 12, how is one to decide
the proportion of patients who failed to experience an
important improvement with placebo? One possible ap-
proach would be, as a first step, to convert the mean
value of the PRO in the control group into proportion
of patients experiencing an improvement of at least one
MID, for each of the studies included in the meta-analysis
[32]. Reviewers could then use the median proportion
across all studies for the conversion of the overall SMD
[21]. The latter problem is ameliorated to some extent
because only at the extremes of control proportions do
Table 3 For situations in which the event is undesirable, reduction [or increase if intervention harmful] in adverse
events with the intervention
Control group response rate 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
SMD = -0.2 -0.03 -0.05 -0.07 -0.08 -0.08 -0.08 -0.07 -0.06 -0.040
SMD = -0.5 -0.06 -0.11 -0.15 -0.17 -0.19 -0.20 -0.20 -0.17 -0.12
SMD = -0.8 -0.08 -0.15 -0.21 -0.25 -0.29 -0.31 -0.31 -0.28 -0.22
SMD = -1.0 -0.09 -0.17 -0.24 -0.23 -0.34 -0.37 -0.38 -0.36 -0.29
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limitation is that the approach, by relying on the SMD,
is vulnerable to whether study populations had very
similar scores on the outcome of interest, or whether
scores were widely variable.
Other statistical approaches also rely on the SMD to
generate dichotomous presentations for continuous out-
comes [22,33]. They share similar limitations, with the
exception that they do not require specification of the
control group response rate, and one approach becomes
unstable when the underlying control group response
rate is less than 20% or greater than 80% [22].
Another strategy for creating dichotomies and generating
estimates of relative and absolute effect relies on know-
ledge of the MID. In applying the approach, we assume
normal distributions of data and then calculate the pro-
portions of participants in the intervention and control
groups in each study that demonstrated an improvement
greater than the MID [25]. The results are then pooled
across studies. Applying this approach in Table 2, findings
suggest small to moderate relative and absolute benefit in
depression as a result of paroxetine therapy (Odds Ratio
1.64; 95% CI 1.47 to 1.84; Risk Difference 0.11; 95% CI
0.07 to 0.16, in favor of paroxetine).
If one only has post-test data (rather than magnitude
of change), one can apply this approach if evidence
exists regarding meaningful thresholds. For instance, if
one knows that people with scores of less than 8 on the
HRSD are considered to be not depressed, one could exam-
ine the proportion of individuals below that threshold.
If such meaningful thresholds do not exist, one can
still use post-test data if one assumes that the minimally
important change within an individual corresponds, on
average, to the minimally important difference between
individuals. Making this assumption, one can calculate the
difference in the proportion who benefit in interventionTable 4 For situations in which the event is desirable, increas
responses to the intervention
Control group response rate 0.1 0.2 0.3
SMD = 0.2 0.04 0.61 0.07
SMD = 0.5 0.12 0.17 0.19
SMD = 0.8 0.22 0.28 0.31
SMD = 1.0 0.29 0.36 0.38and control. To do this, one takes the mean value in the
control group plus one MID unit, and calculates the pro-
portion of patients in each group above that threshold.
Ratio of means
A fourth approach (see row D in Table 2) may appeal to
clinicians: calculate a ratio of means (RoM) between the
intervention and control groups [20]. Advantages of RoM
include the ability to pool studies with outcomes expressed
in different units, avoiding the vulnerability of heteroge-
neous populations that limits approaches that rely on
SD units, and ease of clinical interpretation. However, a
limitation of this RoM method is that it is designed for
post-test scores only.
It is possible to calculate a ratio of change score if both
intervention and control groups change in the same direc-
tion in each relevant study, and this ratio may sometimes
be informative. Limitations include: i) the unlikelihood
of intervention and control group changes in the same
direction in all studies and ii) the possibility of mislead-
ing results if the control group change is very small–in
which case, even a modest change in the intervention
group will yield a large and therefore misleading ratio
of mean changes.
In the paroxetine for depression example (Table 2), the
ratio of means approach suggests a 27% increase in the
mean depression score–meaning that those receiving
paroxetine have a 27% decrease in depression manifes-
tations relative to the placebo control group, an effect
that strikes us as moderate and important.
Minimally important difference units
A final strategy pools across studies in the same way as
the SMD, but instead of dividing the mean difference of
each study by its SD, it divides by the MID associated
with that outcome [14]. The final output, instead of beinge [or decrease if intervention harmful] in positive
0.4 0.5 0.6 0.7 0.8 0.9
0.08 0.08 0.08 0.07 0.05 0.03
0.20 0.19 0.17 0.15 0.11 0.06
0.31 0.29 0.25 0.21 0.15 0.08
0.38 0.34 0.30 0.24 0.17 0.09
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problem of varying SDs across studies that may distort
estimates of effect in approaches that rely on the SMD.
It may, in addition, be more easily interpretable though
it risks the possibility that a difference less than the MID
may be interpreted as trivial when a substantial proportion
of patients have achieved an important benefit. This is
almost certainly an inaccurate interpretation, as con-
version into an absolute risk difference and NNT would
demonstrate (in this case a risk difference of 0.11
equates to an NNT of 9). In addition, to the extent that
the MID estimate is not based on secure evidence, the
approach becomes more questionable [18]. As stated in
the comment in Table 2 (row E), the result for paroxetine
for depression is an effect less than half of one MID, sug-
gesting a small treatment effect. We suggest the following
guide for interpretation: if the pooled estimate is greater
than 1 MID unit, many patients are likely to gain import-
ant benefits from treatment. If the estimate of effect lies
between 0.5 and 1 MID unit, the treatment may benefit an
appreciable number of patients. As the pooled estimate
falls below 0.5 MID units it becomes progressively less
likely that an appreciable numbers of patients will achieve
important benefits from treatment.Natural frequencies and numbers needed to treat
A systematic review of the literature suggests that natural
frequencies (× of 100 people not taking any osteoporotic
drug will suffer a hip fracture over a three year period)
optimizes understanding for most patients and health
professionals [34]. Another approach for readers who
are familiar with the measure is to present the NNT (the
inverse of the proportion benefiting) [23]. Any approach
that yields a proportion can be converted to NNTs.
Furukawa offers an approach based on the binomial and
equal variance assumptions, which meta-analysts usually
presuppose when they resort to standardized mean differ-
ences [21,35]. Tables 3 and 4 shows the results of this
method, which provides the relation between the SMD,
control group response rate, and the resulting risk differ-
ence. Table 3 presents the conversion when the outcome
is undesirable (e.g. depression) and Table 4 when the out-
come is desirable (e.g. response to treatment). The NNT
can be derived from the inverse of the risk difference.Summary and recommendations for enhancing interpretation
We have provided an overview of available methods, in-
cluding the strengths and limitations of the approaches,
for improving the interpretability of pooled estimates
of PROs when trials measure effects using the same in-
strument as well as a diversity of instruments. A complete
summary of strengths and limitations of each of the
methods for pooling diverse instruments, including detailsof the underlying statistical assumptions and methods, is
available in an earlier review [25].
When trials all use the same PRO it is important to
report results beyond a mean difference and statistical
significance as suggested above. When primary studies
have employed more than one instrument it will almost
certainly be informative to report one or more alterna-
tives to the SMD. Calculation and reporting of several
approaches will, if the estimate of effect is of apparently
similar magnitude, be reassuring (and if they are not,
will present a challenge that reviewers should address).
Of the two approaches for converting to natural units
of the most familiar instrument, we recommend re-scaling
the observed means and SDs in the intervention and con-
trol groups over multiplying the SMD by an estimate of
the SD associated with the most familiar instrument
because the former approach does not depend on simi-
larity of patient heterogeneity between studies.
Because of its familiarity to clinicians, in most instances
reviewers might choose to present one of the measures
that generates relative and/or absolute measures of effect.
Of these approaches, if all instruments have an established
MID, we recommend presenting results as a risk differ-
ence with corresponding risks, presented as a natural fre-
quency, in the experimental group and control group
as illustrated in Table 2. Consideration of the relative
advantages and disadvantages of each presentation method
when pooling PRO data will help ensure that data is in-
terpretable to patients, clinicians and other key decision-
makers in the health care domain.
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